StockData

Agios Pharmaceuticals vs Fulcrum Therapeutics

AGIO and FULC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGIO and FULC compare

Agios Pharmaceuticals is the larger company, worth 6.2 times as much as Fulcrum Therapeutics ($1.8B against $286M).

Agios Pharmaceuticals scores higher on the StockData Score (12 against 8 for Fulcrum Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGIOFULC
Size and price
Market cap$1.8B$286M
Share price$29.89$3.75
Change, 1 year−31.5%−56.6%
Change, 5 years−18.0%−75.1%
Beta (5Y)1.541.36
Employees53955
StockData Score
Total score12 (better)8
Valuation score11
Growth score3 (better)0
Performance score2 (better)1
Health score66
Dividend score00
Valuation
P/S18.1×–
P/B1.7×0.9× (better)
FCF yield−20.5% (better)−23.1%
Fair value$27.70–
Margin of safety−7.9%–
Growth
Revenue growth (TTM)141%–
Net income growth (TTM)−163%–
EPS growth (TTM)−163%–
Profitability
Gross margin92.0%–
Operating margin−467%–
Net margin−418%–
FCF margin−371%–
Return on equity−34.3%−32.4% (better)
Return on invested capital−759%−35.0% (better)
Financial health
Debt / equity0.000.00
Current ratio10.2231.35 (better)
Altman Z-score11.45 (better)10.37
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield–−1.5%
Shareholder yield0.00% (better)−1.5%
Ownership
Held by institutions111%112%
Held by insiders1.1%34.7%
Insider net buying, 12 months−$4.9M (better)−$57.5M
Short interest, % of float11.1%12.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.